Przejdź do zawartości
Merck

Przejdź do

539741

PTP1B Inhibitor

≥95% (HPLC), PTP1B inhibitor, solid

Synonim(y):

PTP1B Inhibitor, 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide, PTP Inhibitor XXII

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto
5 mg

Dostępne do wysyłki DZISIAJzKuehne + Nagel Sp. z o.o.

1190,00 zł

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C26H19Br2N3O7S3
Numer CAS:
Masa cząsteczkowa:
741.45
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light

1190,00 zł


Dostępne do wysyłki DZISIAJSzczegóły


Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


Nazwa produktu

PTP1B Inhibitor, PTP1B Inhibitor, CAS 765317-72-4, is a cell-permeable, selective, reversible and non-competitive allosteric inhibitor of PTP1B (IC50 = 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively).

Quality Level

assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

white

solubility

DMSO: 100 mg/mL, ethanol: 5 mg/mL

shipped in

wet ice

storage temp.

−20°C

SMILES string

[S](=O)(=O)(Nc5[s]ccn5)c1ccc(cc1)N[S](=O)(=O)c2cc3[o]c(c(c3cc2)C(=O)c4cc(c(c(c4)Br)O)Br)CC

InChI

1S/C26H19Br2N3O7S3/c1-2-21-23(24(32)14-11-19(27)25(33)20(28)12-14)18-8-7-17(13-22(18)38-21)41(36,37)30-15-3-5-16(6-4-15)40(34,35)31-26-29-9-10-39-26/h3-13,30,33H,2H2,1H3,(H,29,31)

InChI key

SXKBTDJJEQQEGE-UHFFFAOYSA-N

General description

A cell-permeable, selective, reversible, and non-competitive allosteric inhibitor of PTP1B (IC50 = 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively). Binds to a novel site away from the catalytic pocket and inhibits PTP1B activity by preventing closure of the WPD loop. Also available in InSolution format (Cat. No. 539749.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PTP1B403
Product does not compete with ATP.
Reversible: yes
Target IC50: 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Wiesmann, C., et al. 2004. Nat. Struct. Mol. Biol.11, 730.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
539749540211540217
form

solid

form

liquid

form

solid

form

solid

assay

≥95% (HPLC)

assay

≥97% (HPLC)

assay

≥95% (HPLC)

assay

≥95% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

−20°C

storage condition

OK to freeze, protect from light

storage condition

OK to freeze, avoid repeated freeze/thaw cycles, desiccated (hygroscopic), protect from light

storage condition

OK to freeze, protect from light

storage condition

OK to freeze


Klasa składowania

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów



Vitor Ferreira et al.
Redox biology, 63, 102741-102741 (2023-05-26)
Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight gain and metabolic alterations when administered orally to patients. Recently, we demonstrated that, contrarily to the oral treatment which induces weight gain, OLA administered via intraperitoneal (i.p.) in male mice
Sarah Zierold et al.
Journal of the American Heart Association, 10(6), e018322-e018322 (2021-03-06)
Background Brain-derived neurotrophic factor (BDNF) is expressed in neuronal and nonneuronal cells and may affect vascular functions via its receptor, tropomyosin-related kinase B (TrkB). In this study, we determined the expression of BDNF in different perivascular adipose tissue (PVAT) depots
Hyo Jeong Kim et al.
Frontiers in neuroscience, 15, 725398-725398 (2021-10-26)
Rett syndrome (RTT) is a severe X-linked dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene; MeCP2 regulates the expression of brain-derived neurotrophic factor (BDNF) and increasing BDNF levels ameliorates RTT symptoms. However, the clinical application



Numer pozycji handlu globalnego

SKUNUMER GTIN
539741-5MG04055977194302

Questions

Reviews

No rating value

Active Filters